Apogee Therapeutics saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 76 to 86.
IBD's unique RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks matches up against other publicly traded companies.
History reveals that the best-performing stocks typically have an RS Rating north of 80 as they begin their biggest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
Apogee Therapeutics is not currently near a potential buy zone. See if the stock goes on to form a promising consolidation that could kick off a new climb.
The company showed 0% earnings growth in the latest quarterly report. Sales increased 0%.
The company holds the No. 191 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Corcept Therapeutics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
